Venetoclax and ibrutinib and drug combinations for CLL
Results of trial of venetoclax with bendamustine/rituximab or bendamustine/obinutuzumab in CLL
Myeloma 2016: Panel discussion on the status of genomics
Chng Wee Joo et al.
Venetoclax and the future of treatment of multiple myeloma
The epigenetics of multiple myeloma and the rationale for HDAC inhibitors